The first case of thrombosis with thrombocytopenia following the administration of the AstraZeneca vaccine has occurred in Quebec, which was confirmed by the Ministry of Health and Social Services on Tuesday.
The case was traced "in the last days following the administration of a viral vector vaccine against COVID-19, or the AstraZeneca vaccine," according to a press release.
Cases of thrombosis, otherwise known as a blood clot, are "considered to be a possible complication of the vaccine but remain very rare, ie approximately 1 in 100,000 vaccines administered," said the Ministry.
The patient, whose age isn't disclosed, is "recovering at their home and there is no fear for their life."
"Remember that the risks of developing thrombocytopenia with thrombosis as a result of the vaccine are minimal compared to that of complications related to COVID-19. All the vaccines offered in Quebec are safe and have unequivocally demonstrated their effectiveness," highlighted Dr. Horacio Arruda.
UPDATE: An earlier version of this article misstated the cause of the thrombosis case. It has been updated with accurate information from the Ministry of Health and Social Services.
Health Canada has a robust website with all the latest information on the vaccine and can answer any questions you may have. Click here for more information.